MX 1121

Drug Profile

MX 1121

Alternative Names: HYB 101400; MBI 1121; ORI 1001

Latest Information Update: 08 Jun 2007

Price : $50

At a glance

  • Originator Idera Pharmaceuticals
  • Developer MIGENIX
  • Class Antisense oligonucleotides; Antivirals
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Human papillomavirus infections

Most Recent Events

  • 30 Apr 2006 Discontinued - Phase-I for Human papillomavirus infections in Canada (Topical)
  • 22 Sep 2004 Micrologix Biotech is now called MIGENIX
  • 14 Jul 2004 Suspended - Phase-I for Human papillomavirus infections in Canada (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top